Physician profile

John L Jay

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Dallas, TX

NPI 1033170196

$2,239.45

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$211.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,535.26 2019
Medtronic, INC. $306.40 2021-2023 Corevalve Evolut R
Abiomed $154.13 2022
Edwards Lifesciences Corporation $120.49 2019-2022
Abbott Laboratories $44.97 2022
Allergan, INC. $24.88 2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $23.83 2022
Boston Scientific Corporation $16.74 2023 Varithena Administration Pack
Kls-Martin L.P. $12.75 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John L Jay

$2,239.45

in general payments reported 2019-2025

Years
2019-2023
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/1841/john-l-jay

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.